

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 October 2002 (10.10.2002)

PCT

(10) International Publication Number
WO 02/079457 A1

(51) International Patent Classification⁷: C12N 5/00, 5/02, A01N 37/18, 63/00

(21) International Application Number: PCT/US02/09881

(22) International Filing Date: 29 March 2002 (29.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/279,922 29 March 2001 (29.03.2001) US

(71) Applicant (for all designated States except US): **IXION BIOTECHNOLOGY, INC.** [US/US]; Suite N-111, 13709 Progress Boulevard, Box 13, Alachua, FL 32615 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **RAMIYA, Vijayakumar, K.** [IN/US]; 10323 S.W. 82nd Lane, Gainesville, FL 32608 (US). **CLARK, Amy** [US/US]; 1101 S.W. 20th Place, Gainesville, FL 32601 (US).

(74) Agents: **SWANSON, Barry, J.** et al.; Swanson & Bratschun, L.L.C., Suite 330, 1745 Shea Center Drive, Highlands Ranch, CO 80129 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR TRANSDIFFERENTIATION OF NON-PANCREATIC STEM CELLS TO THE PANCREATIC DIFFERENTIATION PATHWAY

(57) Abstract: The subject invention comprises culture methods for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway. It also concerns the endocrine hormones that can be produced by such cultures, and the use of the transdifferentiated cells in the treatment of pancreatic diseases.

WO 02/079457 A1

METHOD FOR TRANSDIFFERENTIATION OF NON-PANCREATIC STEM CELLS TO THE PANCREATIC DIFFERENTIATION PATHWAY

FIELD OF THE INVENTION

5 The subject invention relates to culture methods for the transdifferentiation of non-pancreatic stem cells, and in particular hematopoietic stem cells and mesenchymal stem cells, to the pancreatic differentiation pathway. It also concerns the use of transdifferentiated cells to treat pancreatic disorders.

10 BACKGROUND OF THE INVENTION

Diabetes is a major public health problem. In the United States, sixteen million persons have diabetes (American Diabetes Association, Professional Section Quarterly, Summer 1998). Ocular complications of diabetes are the leading cause of
15 new cases of legal blindness in people ages 20 to 74 in the United States. The risk for lower extremity amputation is 15 times greater in individuals with diabetes than in individuals without it. Kidney disease is a frequent and serious complication of diabetes. Approximately 30 percent of all new patients in the United States being treated for end-stage renal disease have diabetes. Individuals with diabetes are also at
20 increased risk for periodontal disease. Periodontal infections advance rapidly and lead not only to loss of teeth but also to compromised metabolic function. Women with diabetes risk serious complications of pregnancy. Current statistics suggest that the mortality rates for infants of mothers with diabetes is approximately 7 percent.

Clearly, the economic burden of diabetes is enormous. Each year, patients
25 with diabetes or its complications spend 24 million patient-days in hospitals. Diabetes is our nation's most expensive disease with an estimated total annual cost of \$98 billion; however, the full economic impact of this disease is even greater because additional medical expenses often are attributed to the specific complications of diabetes rather than to diabetes itself.

30 Diabetes is a chronic, complex metabolic disease that results in the inability of the body to properly maintain and use carbohydrates, fats, and proteins. It results from the interaction of various hereditary and environmental factors and is characterized by high blood glucose levels caused by a deficiency in insulin production or an impairment of its utilization. Most cases of diabetes fall into two
35 clinical types: Type I, or juvenile-onset, and Type II, or adult-onset. Type I diabetes

is often referred to as Insulin Dependent Diabetes, or IDD. Each type has a different prognosis, treatment, and cause.

Approximately 5 to 10 percent of diabetes patients have IDD. IDD is characterized by a partial or complete inability to produce insulin usually due to destruction of the insulin-producing cells of the pancreatic islets of Langerhans. Patients with IDD would die without daily insulin injections to control their disease. Additionally, a fraction of Type II diabetics are insulin dependent and require insulin injections to improve their insulin resistance. Both Type I and insulin-dependent Type II diabetics can benefit from improvements in insulin administration, such as those described herein.

Few advancements in resolving the pathogenesis of diabetes were made until the mid-1970s when evidence began to accumulate to suggest that Type I IDD had an autoimmune etiopathogenesis. It is now generally accepted that IDD results from a progressive autoimmune response which selectively destroys the insulin-producing cells of the pancreatic Islets of Langerhans in individuals who are genetically predisposed. Autoimmunity to the cell in IDD involves both humoral (Baekkeskov *et al.* (1982) *Nature* 298:167; Baekkeskov *et al.* (1990) *Nature* 347:151; Reddy *et al.* (1988) *Diabetologia* 31:322; Pontesilli *et al.* (1987) *Clin. Exp. Immunol.* 70:84) and cell-mediated (Reddy *et al.* (1988); Pontesilli *et al.* (1987); Wang *et al.* (1987) *Diabetes* 36:535) immune mechanisms. Humoral immunity is characterized by the appearance of autoantibodies to cell membranes (anti-69 kD and islet-cell surface autoantibodies), cell contents (anti-carboxypeptidase A₁, anti-64 kD and/or anti-GAD autoantibody), and/or cell secretory products (anti-insulin). While serum does not transfer IDD, anti-cell autoantibody occurs at a very early age, raising the question of an environmental trigger, possibly involving antigenic mimicry. The presence of cell-mediated immunological reactivity in the natural course of IDD is evidenced by an inflammatory lesion within the pancreatic islets, termed insulitis. Insulitis, in which inflammatory/immune cell infiltrates are clearly visible by histology, has been shown to be comprised of numerous cell types, including T and B lymphocytes, monocytes and natural killer cells (Signore *et al.* (1989) *Diabetologia* 32:282; and Jarpe *et al.* (1991) *Regional Immunol.* 3:305). Adoptive transfer experiments using the NOD (non-obese diabetic) mouse as a model of human IDD have firmly established a primary role for auto-aggressive T lymphocytes in the pathogenesis of IDD (Bendelac, *et al.* (1987) *J. Exp. Med.* 166:823; Miller *et al.* (1988) *J.*

Immunol. 140:52; Hanafusa *et al.* (1988) Diabetes 37:204; and Bendelac *et al.* (1988) J. Immunol. 141:2625). Unfortunately, the mechanisms underlying destruction of the pancreatic cells remain unknown.

The mammalian pancreas controls nutrient resorption and glucose metabolism through its major components, the ductal cells, acinar cells and endocrine cells. The endocrine cells include insulin-produce β cells. Despite the fact that all three components of the pancreas differ in functionality, they are all of the same origin, the primitive gut endoderm. During early gestation (28 days in humans) evaginations of the embryonal foregut form the ventral and dorsal buds of the pancreas. The two buds arise opposite to each other while the gut is still surrounded by primitive mesenchyme. After rotation of the stomach and duodenum, the ventral anlage moves around and fuses with the dorsal bud. The ventral bud forms the posterior part of the pancreatic head including the ulcinate process, while the dorsal bud forms the remainder of the organ. In the enlarging epithelial buds, a treelike ductal system develops which eventually gives rise to endocrine and acinar cells (Peters *et al.* (2000) Virchows Arch. 436:527-538). It is believed that the "protodifferentiated" epithelial cells which reside in the ducts also share the features of ductal cells (Pictet *et al.* (1972) Development of the embryonic endocrine pancreas, In: Geiger SR (ed.) Handbook of Physiology, sect 7: Endocrinology, Waverley Press, Baltimore, pp25-66). These and more recent observations suggest that the pancreatic duct cells harbor the stem cells, which under appropriate stimuli, can give rise to acinar and endocrine cells (Ramiya V. *et al.* (2000) Nat. Med. 6:278-282; Bonner-Weir *et al.* (2000) Proc. Natl. Acad. Sci. USA 97:7999-8004). The pancreatic ductal progenitor stem cells have been shown to express tyrosine hydroxylase (Teitelman *et al.* (1993) Development 118:1031-1039), glucose transporter (GLUT-2) (Pang *et al.* (1994) Proc. Natl. Acad. Sci. USA 91:9559-9563), cytokeratins (Bouwens *et al.* (1994) Diabetes 43:1279-1283), Pdx-1 (Jonsson *et al.* (1994) Nature 371:606-609), high-affinity nerve growth factor TrkA (Kanaka-Gantenbein *et al.* (1995) Endocrinology 136:3154-3162), Isl-1 (Ahlgren *et al.* (1997) Nature 385:257-60), and *ngn-3* (Gradwohl *et al.* (2000) Proc. Natl. Acad. Sci. USA 97:1607-1611). In the human fetal pancreas, proliferation is mainly found in the ductal cell compartment, followed in frequency by endocrine cells, which are synaptophysin positive but hormone negative, and finally, insulin or glucagon positive cells. In addition, it was noted that all epithelial cells, including endocrine cells, express cytokeratin 19 from 12-16

gestation weeks. The cytokeratin disappears later from the endocrine cells (Bouwens *et al.* (1997) *Diabetologia* 40:398-404).

For IDD patients, regular insulin injections do not maintain blood glucose near normal levels at all times and consequently patients develop secondary complications.

5 While pancreatic and islet transplantations can consistently establish a euglycemic state and significantly reduce long-term complications, availability of the grafts is severely limited. Xenotransplants, on the other hand, pose a potentially serious threat of xenosis (transfer of animal infections to humans) with attendant regulatory problems and delays. Thus, there is an urgency to develop a pancreatic endocrine
10 replacement therapy for Type 1 diabetic patients that would supply a sufficient number of functional human islets or their equivalents on demand.

One response to this need has been to develop *in vitro* culture methods for pancreatic differentiated cells or tumor cells (e.g., Gazdar *et al.* (1980) *Proc. Natl. Acad. Sci.* 77(6):3519-3525; Brothers, A., WO 93/00441; Korsgren *et al.* (1993) *J. Med. Sci.* 98(1):39-52; Nielson, J., WO 86/01530; McEvoy *et al.* (1982) *Endocrinol.* 111(5):1568-1575; Zayas *et al.*, EP 0 363 125; and Coon *et al.*, WO 94/23572). Such
15 culture methods could be used to generate endocrine hormones or, in some instances, furnish cells for transplantation.

Another response has been to identify and culture pancreatic stem cells which
20 can give rise to islet progenitor cells (IPCs) and IPC-derived islets (IdIs) or islet-like structures (see U.S. Serial No. 09/406,253, filed September 27, 1999, and Peck *et al.*, WO 01/23528). The advantages of this method include the long-term propagation of the stem cells and the use of the stem cells and their progeny for implantation into patients, wherein they proliferate to form a pancreas-like structure that can restore
25 euglycemia.

Notwithstanding the foregoing, there remains a need to develop additional pancreatic endocrine replacement therapies. The subject invention concerns the use of non-pancreatic stem cells in the development of therapies for IDD. Specifically, non-pancreatic stem cells are transdifferentiated to the pancreatic lineage.

30 A stem cell is a cell that has the capacity to both self-renew and to generate differentiated progeny. Two stem cells that are already in clinical use are hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs). The mammalian hematopoietic system produces at least eight distinct lineages of mature blood cells in a continuous manner throughout adult life. These lineages include red

blood cells, monocytic, granulocytic, basophilic, myeloid cells, the T and B cells and platelets. In this sense, hematopoiesis may resemble other developmental systems such as small intestine, epidermis, and hair follicle of the skin as well as the male germ cells. Other tissue types such as the liver, central nervous system and skeletal muscles seem to replenish more slowly, or in response to injury (Lemischka *et al.* (1986) Cell 45:917-927). Complex quantitative analyses of HSCs, in some cases, demonstrated that a single transplantable stem cell is both necessary and sufficient to transfer an intact, normal hematopoietic system to a recipient host (Jordan *et al.* (1990) Genes Dev. 4:220-232; and Smith L. *et al.* (1991) Proc. Natl. Acad. Sci. 88:2788-2792).

The proliferation and development of HSCs *in vivo* is promoted by contact with bone marrow stromal cells and the surrounding extracellular matrix. While there is some ability of soluble cytokines or growth factors to promote survival and proliferation of stem cells and their progeny in the absence of stromal cell matrix, the primitive HSCs can only be maintained, in the long term, when co-cultured with the appropriate stromal cell environment (Dexter *et al.* (1990) Ciba Found. Symp. 148:76-86). The characterization of CD34 antigen on HSCs, expressed only by 0.5-5% of human bone marrow cells, has enabled the purification of HSCs in commercial quantities. CD34 is not expressed on more mature counterparts (Civin *et al.* (1990) Prog. Clin. Biol. Res. 333:387-401). Using the long term bone marrow culture system, it has been established that CD34+ HSCs can survive *in vitro* and differentiate when allowed to grow in contact with bone marrow derived stromal cells, which produce a plethora of factors including M-CSF, GM-CSF, G-CSF, IL-1, IL-6, IL-7, TGF-beta, LIF, SCF (Heyworth *et al.* (1997) In: Stem Cells, Academic Press Ltd., pp243-441).

Both HSCs and MHCs have been suggested to share common bone marrow precursors that express CD34 antigen. Accordingly, CD50- and CD34+ cells give rise to MSCs, while CD50+ CD34+ cells give rise to HSCs. Also, circulating cells include fibroblast-like MSCs (also called fibrocytes) along with HSCs. The MSCs can differentiated into osteocytes, adipocytes and chondrocytes *in vitro* when appropriate growth factors are provided (Pittenger *et al.* (1999) Science 284:143-146).

Although less extensive, other studies have identified candidate stem cells from a number of other tissues (Reynolds *et al.* (1992) Science 255:1707-1710; Johansson *et al.* (1999) Cell 96:25-34; Potten *et al.*, Int. J. Exp. Pathol. 78:219-243;

Watt F (1998) *Philos. Trans. R. Soc. London B* 353:831-837; Alison M (1998) *Curr. Opin. Cell Biol.* 10:710-715; and Ramiya V. *et al.* (2000) *Nat. Med.* 6:278-282).

Recent progress in stem cell biology puts the traditional view that a cell's fate is sealed when it becomes part of endoderm, mesoderm, or ectoderm, the primary germ layers of the embryo, in paradox. More specifically, the assumption that the undifferentiated stem cell state as defined by the ability of stem cell to produce mature cell populations is limited to the range of cell types characteristic of each individual tissue (by implication, any given somatic stem cell is physically resident within its appropriate tissue) has been called into question (Lemischka I. (1999) *Proc. Natl. Acad. Sci. USA* 96:14193-14195). For instance, after transplantation into irradiated hosts, genetically labeled neural stem cells were found to produce a variety of blood cell types including myeloid and lymphoid cells as well as early hematopoietic cells (Bjornson *et al.* (1999) *Science* 283:534-537). The muscle tissue has been shown to contain a population of stem cells with several characteristics of bone marrow-derived HSCs, including high efflux of the fluorescent dye Hoechst 33342 and expression of the stem cell antigens Sca-1 and c-Kit but not CD45. These stem cells have been suggested to be identical to muscle satellite cells, some of which lack myogenic regulators and which are capable of responding to hematopoietic signals (Jackson *et al.* (1999) *Proc. Natl. Acad. Sci. USA* 96:14482-14486). A similar observation has been made by another group who also demonstrated the muscle differentiation potential of a subset of bone marrow-derived stem cells (Gussoni *et al.* (1999) *Nature* 401:390-394). A possibility of HSCs mobilizing during liver failure to increase the regenerative capacity of the liver, though to a lesser extent, has been documented (Alison *et al.* (2000) *Nature* 406: 257). These observations invite speculation that the functional plasticity of somatic tissue derived stem cells may be greater than expected.

HSCs and MSCs are presently routinely used in the clinical setting and are commercially available. They can be purified from the peripheral blood or bone marrow using commercially available technology. Obtaining pancreatic endocrine tissue or hormones from HSCs or MSCs that have committed to the pancreatic differentiation pathway would be very useful in advancing the treatment of diabetes.

SUMMARY OF THE INVENTION

The subject invention concerns a method of directing or transdifferentiating mammalian non-pancreatic stem cells to enter the pancreatic differentiation pathway by culturing said stem cells in a medium under conditions that permit the expression of pancreatic differentiation markers. The medium used in the method can be any suitable medium, but in a preferred embodiment, comprises Dulbecco's Minimal Essential Medium (DMEM) with high glucose and sodium pyruvate, bovine serum albumin (BSA), 2-mercaptoethanol, fetal calf serum (FCS), penicillin and streptomycin (Pen-Strep), and insulin, transferrin and selenium (ITS) for at least about 10-14 days. Preferably, the concentrations of the medium components are as indicated in Table 1A. The subject method results in expression of any or all of the following pancreatic markers: Pdx-1, Isl-1, Pax-4, Pax-6, Glut-2, CK-19 and insulin.

The medium may further contain an effective combination and effective concentrations of suitable growth factors, including those selected from the group consisting of stem cell factor (SCF), glucagon-like peptide-1 (GLP-1), activin A, betacellulin, hepatocyte growth factor (HGF), epidermal growth factor (EGF), keratinocyte growth factor (KGF), prolactin (PRL), nerve growth factor (NGF), transforming growth factor- α (TGF- α), gastrin, and conditioned medium of a cell line selected from the group consisting of Capan-1, ARIP and AR42J. Preferably, the added growth factors include each of these factors in the concentrations indicated in Table 1B. To enhance commitment to the pancreatic pathway, LIF (leukocyte inhibiting factor, which inhibits HSC differentiation), and IL-3 and IL-7 (which induce HSC commitment to lymphoid and erythroid lineages) are omitted from the Table 1B factors.

The non-pancreatic stem cells can be any stem cell other than the pancreatic stem or progenitor cells, but are typically HSCs or MSCs. The HSCs are CD34+, and the MSCs are CD105+, CD166+, CD29+ and CD44+. HSCs can be obtained from peripheral blood or from bone marrow. MSCs can also be obtained from bone marrow. The stem cells may be human or those of any other mammal.

The subject invention also comprises a method of producing an endocrine hormone by culturing stem cells in the medium with added factors as described above, whereby an endocrine hormone is produced and optionally recovered. The subject invention also encompasses the endocrine hormones produced by this method.

In another embodiment, the subject invention is directed to a method of treating a mammal with a pancreatic disorder, by culturing stem cells as described herein whereby the cells enter the pancreatic differentiation pathway, and using a product of the culture method to treat the mammal. In one embodiment, the
5 pancreatic disorder is insulin-dependent diabetes (IDD) .

In one case, the culture product that is administered to the mammal is one or more pancreatic endocrine hormones. The culture product may also be the transdifferentiated HSCs and MSCs, which may be implanted in the mammal. Typical locations for implantations of such cells are liver, pancreatic or kidney tissue,
10 or in a subcutaneous pocket. It is preferred that, where implantation is contemplated, the non-pancreatic stem cells originate from the same species, and more preferably, the same individual that is to be treated so as to minimize the potential for immune rejection. The stem cells and the individual to be treated may be human or any other mammal.

15 Where there is some question of immune rejection, the cells or aggregates of cells that are to be implanted in the individual can be encapsulated in a hormone permeable capsule. Such capsule permits the flow of hormones from the implanted material, and the influx of oxygen and other nutrients, while inhibiting the influx of immune cells and antibodies.

20 Additionally, the transdifferentiated cells can be protected from immune rejection by modifying cell expression of selected proteins. For example, the cultured transdifferentiated cells can be transformed to express a protein or peptide which will inhibit or prevent the destructive immune process. Other useful proteins or peptides may be expressed. In addition, expression of autoantigens specific to the IDD
25 process, such as GAD, 64 kD islet cell surface antigens (see Payton *et al.* (1995) J. Clin. Invest. 96:1506-1511), to the extent they may be expressed by the transdifferentiated cells, or any other markers identified on the transdifferentiated cells, can be eliminated by standard gene knock-out or selection procedures to
30 produce transdifferentiated cells which are not or are less susceptible to autoimmune attack. Methods for producing such mutant or knock out cells are well known in the art and include, for example, homologous recombination methods disclosed in U.S. Patent No. 5,286,632; U.S. Patent No. 5,320,962; U.S. Patent No. 5,342,761; and in WO 90/11354; WO 92/03917; WO 93/04169; WO 95/17911, all of which are herein incorporated in their entirety by reference. In addition, a universal donor cell is

produced by preparing transdifferentiated cells modified so as not to express human leukocyte antigen (HLA) markers (see especially WO 95/17911).

The subject invention encompasses not only the methods described above, but also the transdifferentiated HSCs and/or MSCs produced by the methods. It also encompasses transdifferentiated HSCs that express mRNA for *Isl-1*, *Pax-6*, *CK-19* and optionally *insulin*. It further includes the transdifferentiated MSCs that express mRNA for *Isl-1*, *Pax-6*, *Glut-2*, *glucagon* and optionally *Pdx-1* and/or *Pax-4*.

All references cited herein are incorporated in their entirety by reference.

10

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 illustrates the mRNAs for *Isl-1*, *Pax-6*, *CK-19* and *CD34* that were expressed after two weeks of culturing of HSCs in basal medium plus Table 1B factors. Continuous culture for 45 days resulted in the expression of mRNA for insulin and continued expression of CK19 mRNA.

15

Figure 2 illustrates the mRNAs for *Pdx-1*, *Isl-1*, *Pax-4*, *Pax-6*, *Glut-2*, *CK-19* and *CD34* that were expressed by a mixed culture of HSCs and MSCs for 14 days in basal medium alone.

Figure 3 shows the spherical morphology of the transdifferentiated HSCs and the spindle-shaped morphology of the transdifferentiated MSCs.

20

DETAILED DESCRIPTION OF THE INVENTION

The subject invention demonstrates for the first time the potential of non-pancreatic stem cells, and in particular, human bone marrow-derived stem cells (HSCs and MSCs) to differentiate into insulin gene expressing cells. The stem cells that are employed in the subject culture method can be any non-pancreatic stem cell, or may be limited to non-pancreatic stem cells that are not liver stem or progenitor cells (hepatoblasts or liver oval cells), or can specifically be MSCs and/or HSCs.

"Stem cell" is defined as a cell that has the capacity to both self-renew and to generate differentiated progeny. In one embodiment of the invention, non-pancreatic stem cell refers to any non-pancreatic stem cell, presently known or later discovered. In this broadest sense, non-pancreatic stem cells can include, without limitation, embryonic stem cells, adult non-pancreatic stem/progenitor cells, de-differentiated stem/progenitor cells, and multipotent adult stem cells. While stem cells have the capacity to both self-renew and to generate differentiated progeny, progenitor cells

have only the capacity to generate differentiated progeny. The non-pancreatic stem cell of the subject invention is mammalian, and may or may not be human.

Embryonic stem cells have been isolated for a number of mammalian species, including human. Human embryonic stem cells are SSEA-1(-); SSEA-3(+); SSEA-4(+); TRA-1-60(+); TRA-1-81(+); and alkaline phosphatase (+). These cells can proliferate *in vitro* indefinitely in an undifferentiated state and are capable of differentiating into endoderm, mesoderm and ectoderm. See U.S. Pat. Nos. 6,200,806 and 5,843,780.

Adult non-pancreatic stem/progenitor cells include, without limitation, hepatic stem/progenitor cells (hepatoblasts or oval cells), mesenchymal stem/progenitor cells, neural stem/progenitor cells, adipocyte stem/progenitor cells, hematopoietic stem/progenitor cells, and skeletal muscle satellite stem/progenitor cells. As used herein "adult" stem cells refer to those tissue specific stem cells that are not embryonic, i.e., from fetal, neonatal, juvenile and adult individuals.

For example, hepatic oval cells and hepatoblasts have been described in Yin, L. *et al.* (1999) J. Hepatol. 31:497-507, Yin, L. *et al.* (2001) PAACR 42:354, and Yin, L. *et al.* (2001) FASEB J. Late-Breaking Abstracts:49 (LB267). The oval cells are critical in the repair of periportal liver injury. Liver hepatoblast and oval cell markers include α -fetal protein, albumin, cytokeratin 14 (CK14), c-kit, OC.2, OC.3, OC.10, OV1 and OV6. Hepatoblasts and oval cells can also express hematopoietic markers, including CD34, Thy1.1 and CD45. It is not yet known whether oval cells themselves are liver stem cells, or are progenitor cells derived from a liver stem cell or HSCs. RT-PCR investigations of liver oval cells indicate that these cells express not only insulin I and insulin II transcripts but also express RNA transcripts for transcription factors *Isl1*, *NeuroD/β2*, *Nkx6.1*, and *Pax4*. These transcription factors have important roles in regulating differentiation of pancreatic cells to endocrine cells.

MSCs are described in U.S. Pat. No. 5,486,359. Human MSCs are self-renewing and can differentiate into bone (osteoblasts), cartilage (chondrocytes) and various other types of connective tissue (adipose, muscle, tendon, ligament and dermis). MSCs available from Clonetics (Walkersville, MD) are SH2+, SH3+, CD105+, CD166+, CD29+, CD44+, CD45- and CD34- and are obtained from bone marrow.

Fetal MSCs are described in WO 01/34775 as CD34+, CD45-, Thy-1+, AS-O2+ and SH2+ (CD105+). These cells can be used to regenerate osteoblasts, adipocytes, fibroblasts, muscle cells or cartilage.

Substantially homogeneous human HSCs are described in U.S. Pat. Nos. 5,061,620 and 5,750,397. These cells are CD34+ and Thy1+, and may be obtained from bone marrow, fetal liver, fetal and adult spleen and blood. These cells are capable of regenerating all members of the various hematopoietic (myeloid and lymphoid) lineages.

Human HSCs are also described in U.S. Pat. No. 5,840,580 as being CD34+ and CD38-, and preferably HLA-DR+. By excluding CD38+ cells, mature and progenitor cells are removed, and the selected cells are non-lineage committed with multi-lineage potential. These stem cells are capable of limited self-renewal and can differentiate into erythroid, myeloid and lymphoid progenitors and mature cells.

Human pluripotent lympho-hematopoietic stem cells are described in U.S. Pat. No. 4,714,680. These cells are My-10+ or CD34+. These cells are found in human marrow or among blood colony-forming cells and immature lymphoid precursor cells, but do not include mature human lymphoid and myeloid cells. The My-10 antigen is not lineage dependent, but appears on a variety of lympho-hematopoietic progenitor cells.

Skeletal muscle satellite cells share several characteristics of bone marrow-derived HSCs including expression of antigens Sca-1 and c-Kit, but not CD45 (Jackson K. *et al.* (1999) PNAS 96:14482-86)). Quiescent muscle satellite cells *in vivo* are CD34+, Myf5+, M-cadherin+ and MyoD-; these cells are committed to the myogenic pathway, but are arrested until injury or growth stimuli are received (Beauchamp *et al.* (2000) J. Cell Biol. 151:1221). There is also evidence that muscle satellite cells may replenish the hematopoietic systems of lethally irradiated recipients (Goodell *et al.* (2001) Ann. NY Acad. Sci. 938:18). Highly purified HSCs from bone marrow have been reported to participate in muscle regeneration; and skeletal muscle stem cells have been reported to reconstitute the hematopoietic compartment. There is also speculation that satellite cells may be derived from embryonic vasculature (Seal, P. *et al.* (2000) Dev. Biol. 218:115). At this time, it remains unclear whether skeletal muscle satellite cells are skeletal muscle stem or progenitor cells.

Neural crest stem cells are described in U.S. Pat. No. 5,589,376. These cells are low-affinity nerve growth factor receptor (LNGFR)+ and nestin+, are

characterized by the absence of markers associated with mature peripheral nervous system neuronal and glial cells, and are capable of self-renewal and differentiation to peripheral nervous system neuronal and glial cells. Such glial cell markers include sulfatide, glial fibrillary acidic protein (GFAP) and myelin protein P₀, and neuronal markers include peripherin and neurofilament.

Adipose-derived stem cells are described in WO 00/53795. These cells are substantially free of adipocytes, erythrocytes and clonal populations of connective tissue stem cells. The stem cell is not defined in terms of markers, but is instead defined as being capable of achieving two or more developmental phenotypes selected from the following: adipogenic, chondrogenic, cardiogenic, dermatogenic, hematopoietic, hemangiogenic, myogenic, nephrogenic, neurogenic, neuralgiogenic, urogenitogenic, osteogenic, pericardiogenic, peritoneogenic, pleurogenic, splanchnogenic, and stromal developmental phenotypes.

De-differentiated cells include stem/progenitor cells obtained by de-differentiating somatic cells. Such technique involves the injection of cell cytoplasm from a less differentiated donor cell into a recipient cell, as described in WO 01/00650. The donor cell can be an oocyte or embryonic cell. This method can result in an embryonic stem cell.

Multipotent adult stem cells (MASCs), described in WO 01/11011, can be derived from brain, liver or bone marrow, and are CD45- CD44- HLA-DR- HLAclassI- oct3/4mRNA+ and hTRT+. Using appropriate growth factors, chemokines and cytokines, MASCs can be differentiated into bone, cartilage, adipocyte, fibroblast, marrow stroma, skeletal muscle, smooth muscle, cardiac muscle, endothelial, epithelial, endocrine, exocrine, hematopoietic, glial, neuronal and oligodendrocyte cells. The MASC cells express genes (oct-4 and Rex-1) commonly found only in embryonic stem or embryonic germ cells. A full description of marker phenotype for human MASCs is provided on pages 26-27 of WO 01/11011.

In another embodiment, non-pancreatic stem cells can mean all non-pancreatic stem cells provided that the stem cells are not liver stem or progenitor cells (i.e., hepatoblasts and liver oval cells).

In another embodiment, non-pancreatic stem cells simply means HSCs and/or MSCs. Without wishing to be bound by theory, it is believed that the MSCs and HSCs are particularly amenable to transdifferentiation using the subject method because these cells continuously regenerate and replenish differentiated mesenchymal

and hematopoietic populations throughout the lives of mammals. Other stem cells having similar regeneration and replenishment capacities may likewise be useful in the subject methods.

The subject invention's culture method for transdifferentiation of non-pancreatic stem cells to the pancreatic lineage preferably utilizes the culture conditions specified in Tables 1A and 1B. However, the concentrations specified in Tables 1A and 1B may be further optimized, and some components may be determined to be optional, using routine methods known in the art. Additionally, the subject invention can be practiced using medium and added factor concentrations that vary by 10-50% from those indicated in Tables 1A and 1B, without significantly impairing, and possibly improving, the outcome of the method. By using routine methods of optimization, the skilled artisan can determine an effective combination and effective concentration of the components listed in Tables 1A and 1B. In Table 1A, fetal calf serum and bovine serum albumin are specified. These components may be replaced by equivalent human serum or albumin, or fractions or specific compounds therein that permit or enhance transdifferentiation of stem cells to the pancreatic lineage.

In Table 1B, the conditioned medium of the epithelial cell lines, Capan-1, ARIP and AR42J, is preferably obtained from a confluent flask of cells cultured in 1640 medium with 10% fetal calf serum for at least one week. The FCS can be replaced by equivalent human serum or active fractions or specific compounds found therein.

The products of the subject culture method include endocrine hormones and the transdifferentiated stem cells. The endocrine hormones include insulin, somatostatin, glucagon and/or pancreatic polypeptide.

The transdifferentiated stem cells express (as mRNA and/or polypeptides) pancreatic markers including Pdx-1, Isl-1, Pax-4, Pax-6, Glut-2, CK-19, glucagon and/or insulin. Preferably, the transdifferentiated HSCs express at least Isl-1, Pax-6, CK19 and insulin. Preferably, the transdifferentiated MSCs express at least Pdx-1, Isl-1, Pax-4, Pax-6, Glut-2 and glucagon. The transdifferentiated cells vary in morphology depending on the starting stem cell. MSCs are spindle-shaped, and the transdifferentiated MSCs remain substantially spindle-shaped. Likewise, HSCs are round cells and their transdifferentiated product is also round. It may be that with continued culture and/or the addition of factors that further enhance pancreatic

differentiation, that the morphology of the transdifferentiated cells will become similar to that of pancreatic progenitor or differentiated endocrine cells (α , β , δ and PP cells).

5 The treatment methods of the subject invention include harvesting of endocrine hormones (especially insulin) from the cultured transdifferentiated cells, using methods known in the art, and administering the hormone to a patient. Another treatment method of the invention involves the implantation of transdifferentiated cells that produce endocrine hormones into individuals in need thereof. The subject invention provides a method of controlling or eliminating a diabetic (IDD) patient's
10 need for insulin therapy because the transdifferentiated cells can produce insulin *in vivo*. Thus, the subject implantation method can be used to treat or reverse IDD. Sites of implantation include in the liver, natural pancreas, under the kidney capsule or in a subcutaneous pocket.

The appropriate cell implantation dosage in humans can be determined from
15 existing information relating to *ex vivo* islet transplantation in humans, further *in vitro* and animal experiments, and from human clinical trials. From data relating to transplantation of *ex vivo* islets in humans, the number of transdifferentiated cells per patient kg can be calculated, according to the hormone production of the cells. Assuming long-term survival of the implants following transplantation (e.g., in the
20 case of encapsulation), less than the number of β cells in *ex vivo* islet transplantation may be necessary. From *in vitro* culture and *in vivo* animal experiments, the amount of hormones produced can be quantitated, and this information is also useful in calculating an appropriate dosage of implanted material. Additionally, the patient can be monitored to determine adherence to normoglycemia. If such testing indicates an
25 insufficient response or hyperinsulinemia, additional implantations can be made or implanted material reduced accordingly.

As discussed above, it is preferred that the transdifferentiated cells be derived from the patient that is being treated so as to avoid immune rejection. However, where autologous cells are not available, it can be useful to encapsulate the
30 transdifferentiated cells in a capsule that is permeable to the endocrine hormones, including insulin, glucagon, somatostatin and other pancreas produced factors, yet impermeable to immune humoral factors and cells. Preferably the encapsulant is hypoallergenic, is easily and stably situated in a target tissue, and provides added protection to the implanted structure..

Protection from immune rejection can also be provided by genetic modification of the transdifferentiated cells, according to any method known in the art. Autoantibody and CTL resistant cells can be produced using methods such as those disclosed in U.S. Patent No. 5,286,632; U.S. Patent No. 5,320,962; U.S. Patent
5 No. 5,342,761; and in WO 90/11354; WO 92/03917; WO 93/04169; and WO 95/17911. Alternatively, selection of resistant transdifferentiated cells (e.g., HSCs and/or MSCs) is accomplished by culturing these cells in the presence of autoantibody or IDD associated CTLs or CTLs activated with IDD specific autoantigens. As a result of these techniques, cells having increased resistance to destruction by antibody
10 or T-lymphocyte dependent mechanisms are generated. Such cells can be implanted into an appropriate host in an appropriate tissue as disclosed herein and have increased resistance to destruction by autoimmune processes.

Likewise, the human leukocyte antigen (HLA) profile of the transdifferentiated cell (e.g., HSC or MSC) can be modified, optionally by an iterative
15 process, in which the transdifferentiated cell is exposed to normal, allogeneic lymphocytes, and surviving cells selected. Alternatively, a site directed mutagenesis approach is used to eliminate the HLA markers from the surface of the transdifferentiated cells, and modified transdifferentiated cells thereby generated are implanted into a recipient mammal in need of such implantation.

20 In a specific example, the adeno-associated virus (AAV) vector system carrying the neomycin-resistance gene, *neo* is used. AAV can be used to transfect eukaryotic cells (Laface *et al.* (1988) Virology 162:483-486). In addition, the pBABE-bleo shuttle vector system carrying the phleomycin-resistance gene is used (Morgenstein *et al.* (1990) Nucleic Acids Res. 18:3587-3596). This shuttle vector can
25 be used to transform human cells with useful genes as described herein.

EXAMPLE

Upon receipt of the HSCs, they were cultured in basal medium (Table 1A) for two days. After two days of rest, the cells were split into groups and cultured in
30 various factors. After 14 and 45 days, RNA was extracted for RT-PCR/Southern blot analyses to determine the expression of genes relevant to pancreas organogenesis, and not known to be involved in hematopoietic or mesenchymal pathways of differentiation. These genes include *Isl-1*, *Pdx-1*, *Pax -4*, *Pax-6*, *Glut-2* and *insulin*. Human bone marrow-derived CD34+ stem cells treated with basal medium containing

various factors (Table 1B) for 2 weeks expressed mRNAs for *Isl-1*, *Pax-6*, *CK-19* along with *CD34* (Figure 1). The continuous culture of cells up to 45 days resulted in the expression of mRNA for insulin and maintenance of CK19 (Figure 1).

Interestingly, human bone marrow-derived CD34+ HSCs that contained MSCs as well, after 14 days of culture period in basal medium alone (Table 1A), expressed mRNAs for *Pdx-1*, *Isl-1*, *Pax-4*, *Pax-6*, *Glut-2*, *CK-19* along with *CD34* (Figure 2). At the time of analysis, the majority of the cells were expressing typical MSC morphology (Figure 3).

MSCs thawed immediately upon arrival and rested for 2 days in basal medium, were split into 3 groups: basal medium alone, basal medium plus factors with no conditioned medium, and basal medium with factors and conditioned medium (as set forth in Table 1B). After 21 days of culture, MSCs expressed mRNAs for *Pdx-1*, *Isl-1*, *Pax-4*, *Pax-6*, *Glut-2*, and *glucagon* along with *CD34* but not for *insulin* (data not shown). While *Isl-1* expression is seen in all 3 groups, *Pdx-1* and *Pax-4* appear only when factors/conditioned medium are included. Glucagon mRNA expression is also seen even in the absence of insulin expression. The level of Glut2 mRNA expression is increased upon culturing with factors. The presence of CD34 message is interesting since undifferentiated MSCs are considered to be negative for CD34 by the cell supplier (Clonetics). At the time of analysis, a majority of the MSCs exhibited a spindle-shaped fibroblastic morphology. The HSCs exhibit both adherent and round suspension cells in the culture.

Thus, we are able to direct bone marrow-derived hematopoietic stem cells (that normally give rise to red blood cells, monocytic, granulocytic, basophilic, myeloid cells, T and B cells and platelets), and MSCs (that normally give rise to adipocytes, chondrocytes and osteocytes (Pittenger MF, *et al.* (1999) Science 284:143-146)) to enter into the pancreatic differentiation pathway.

TABLE 1A - Basal Medium Components

DMEM with 4500 mg/L glucose and 110 mg/L sodium pyruvate (Dulbecco's Minimal Essential Medium, Gibco-BRL)
 1% bovine serum albumin (BSA)
 0.1mM 2-Mercaptoethanol
 15% fetal calf serum (FCS)
 Pen-Strep 1X (Gibco-BRL)
 ITS (insulin, transferrin and selenium) 1X (Gibco-BRL)

TABLE 1B - Added Factors

	SCF (stem cell factor) 10ng/ml
	GLP-1 (glucagon-like peptide) 10nM
5	Activin A 1nM
	Betacellulin 5nM
	HGF (hepatocyte growth factor) 20ng/ml
	EGF (epidermal growth factor) 20ng/ml
	KGF (keratinocyte growth factor) 20ng/ml
10	PRL (prolactin) 100 pg/ml
	NGF (nerve growth factor) 3ng/ml
	TGF-alpha (transforming growth factor) 10ng/ml
	Gastrin 10ug/ml
	Conditioned medium (of Capan-1, ARIP and AR42J cell lines) 10%

15

It should be understood that the example and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

Claims

1. A method of transdifferentiating mammalian non-pancreatic stem cells to enter the pancreatic differentiation pathway, comprising:

5 culturing said stem cells in a medium that permits the expression of pancreatic differentiation markers.

2. The method of claim 1 wherein said medium comprises Dulbecco's Minimal Essential Medium (DMEM) with high glucose and sodium pyruvate, bovine serum
10 albumin (BSA), 2-mercaptoethanol, fetal calf serum (FCS), penicillin and streptomycin (Pen-Strep), and insulin, transferrin and selenium (ITS) for at least about 10-14 days.

3. The method of claim 1 wherein the pancreatic markers that are expressed are
15 selected from the group consisting of *Pdx-1*, *Isl-1*, *Pax-4*, *Pax-6*, *Glut-2*, *CK-19* and *insulin*.

4. The method of claim 1, wherein the medium further contains an effective combination and effective concentration of growth factors selected from the group
20 consisting of stem cell factor (SCF), glucagon-like peptide-1 (GLP-1), activin A, betacellulin, hepatocyte growth factor (HGF), epidermal growth factor (EGF), keratinocyte growth factor (KGF), prolactin (PRL), nerve growth factor (NGF), transforming growth factor- α (TGF- α), gastrin, and conditioned medium of a cell line selected from the group consisting of Capan-1, ARIP and AR42J.

5. The method of claim 4 wherein the growth factors comprise SCF, GLP-1, activin A, betacellulin, HGF, EGF, KGF, PRL, NGF, TGF- α , gastrin and conditioned
25 medium of a cell line selected from the group consisting of Capan-1, ARIP and AR42J.

6. The method of claim 1 wherein said non-pancreatic stem cells are selected from the group consisting of hematopoietic stem cells (HSCs) and mesenchymal stem
30 cells (MSCs).

7. The method of claim 6 wherein the HSCs are CD34+.
8. The method of claim 6 wherein the MSCs are CD105+, CD166+, CD29+ and CD44+.
- 5 9. The method of claim 1 wherein the stem cells are human.
10. A method of producing an endocrine hormone comprising the method of claim 1, and further comprising the step of continuing to culture said transdifferentiated cells in said medium, whereby an endocrine hormone may be produced.
11. The endocrine hormones produced by the method of claim 9.
12. A method of treating a mammal with a pancreatic disorder, comprising:
 - 15 a) culturing non-pancreatic stem cells according to claim 1, whereby said stem cells enter the pancreatic differentiation pathway;
 - b) using a product of the culture of step (a) to treat said mammal.
13. The method of claim 12 wherein the pancreatic disorder is insulin-dependent diabetes.
14. The method of claim 12 wherein the product in step (b) is an endocrine hormone that is administered to the mammal.
- 15 15. The method of claim 12 wherein the product of claim 12, step (b), is transdifferentiated cells, and said method further comprises:
 - c) implanting said product in said mammal.
16. The method of claim 15, wherein said implantation is in pancreatic, kidney or liver tissue, or in a subcutaneous pocket.
17. The method of claim 15, wherein said transdifferentiated cells are selected from the group consisting of transdifferentiated HSCs and transdifferentiated MSCs.

18. The method of claim 15, wherein said transdifferentiated cells are modified to substantially reduce expression of an antigen selected from the group consisting of insulin dependent diabetes associated autoantigens, GAD, 64 kD islet cell surface antigen and human leukocyte antigens, whereby the modified transdifferentiated cells
5 do not substantially express said antigen.

19. The method of claim 12, wherein the non-pancreatic stem cells originate from an individual that is the same as the treated mammal of step (b).

10 20. The method of claim 15, wherein said implanted transdifferentiated cells are encapsulated in an endocrine hormone permeable capsule.

21. The method of claim 12, wherein the stem cells are human.

15 22. The transdifferentiated MSC produced by the method of claim 17.

23. A transdifferentiated MSC that expresses mRNA for *Isl-1*, *Pax-6*, *Glut-2*, *glucagon* and optionally *Pdx-1* or *Pax4*.

20 24. The transdifferentiated HSC produced by the method of claim 17.

25. A transdifferentiated HSC that expresses mRNA for *Isl-1*, *Pax-6*, *CK-19* and optionally *insulin*.

25 26. The transdifferentiated cell produced by the method of claim 1.

27. A therapeutic composition comprising a transdifferentiated MSC or transdifferentiated HSC encapsulated in an endocrine hormone permeable capsule.

Treatment of CD34+ Stem Cells With Factors












Figure 1

Mesenchymal Stem Cells Cultured For 14 Days in Basal Medium


G3PDH	
PDX-1	
ISL-1	
PAX 6	
PAX 4	
CK19	
CD34	
Glut2	

BEST AVAILABLE COPY

BEST AVAILABLE COPY

Figure 2

Human Bone Marrow-Derived CD34+ Stem Cells




Basal Medium



Basal Medium+Factors

Mesenchymal Stem Cells



Basal Medium

Figure 3

BEST AVAILABLE COPY

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/09881

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 5/00, 5/02; A01N 37/18, 63/00

US CL : 424/93.7; 435/325, 375, 377, 384, 389; 514/2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/93.7; 435/325, 375, 377, 384, 389; 514/2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
WEST, STN, BIOSIS, SCISEARCH, MEDLINE, CAPLUS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SONG et al. Expansion of Pdx1-Expressing Pancreatic Epithelium and Islet Neogenesis in Transgenic Mice Overexpressing Transforming Growth Factor α . Gastroenterology. 1999, Vol. 117, pages 1416-1426, especially abstract.	1, 3, 9, 26
--		----
Y		4, 12, 13, 21
Y	WO 97/17086 A2 (TAKEDA CHEMICAL INDUSTRIES LTD.) 15 May 1997, abstract, pages 23-25.	4, 12, 13, 21

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

23 JULY 2002

Date of mailing of the international search report

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SHIN-LIN CHEN

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet) (July 1998)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US02/09881

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to
such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report
covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)*

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/09881

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-9, drawn to a method of transdifferentiating mammalian non-pancreatic stem cells to enter pancreatic differentiation pathway comprising culturing said stem cells in a medium, wherein the pancreatic markers could be Pdx-1, Isl-1, Pax-4, Pax-6, Glut-2, Ck-9 or insulin.

Group II, claim(s) 10 and 11, drawn to a method of producing an endocrine hormone comprising the method set forth above and the production of endocrine hormone.

Group III, claim(s) 12-14, 19 and 21, drawn to a method of treating a mammal with a pancreatic disorder comprising culturing non-pancreatic stem cells according to the method set forth above and use endocrine hormone produced from the cultured cells to treat said mammal.

Group IV, claim(s) 12, 13, 15-18 and 20, drawn to a method of treating a mammal with a pancreatic disorder comprising culturing non-pancreatic stem cells according to the method set forth above and use the cultured transdifferentiated cells to treat said mammal.

Group V, claim(s) 22-27, drawn to a transdifferentiated cell produced by the method set forth above, or a transdifferentiated HSC or MSC.

The inventions listed as Groups I-V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The technical feature shared by groups I-V is the transdifferentiated cells that produce endocrine hormones. Song et al., 1999 (Gastroenterology, Vol. 117, No. 6, p. 1416-1426) teaches overexpression of TGF-alpha induces expansion of a Pdx-1-expressing epithelium in a transgenic mice characterized by focal expression of Pax6 and initiation of islet neogenesis. Takeda Chemical Industries (WO 97/17086) teaches using activin A and human betacellulin protein to stimulate differentiation of AR42J cells, derived from a pancreatic cancer induced by a chemical carcinogen, to insulin-producing beta cells. According to the teachings of Song and Takeda Chemical Industries, no special technical feature is contributed over the prior art. An endocrine hormone and a transdifferentiated cell are different products that differ in their chemical structures, physical properties and biological functions. Further, the methods of groups I-V differ in their method process, doses and reagents used, variables and criteria of success. Thus, groups I-V do not relate to a single inventive concept under PCT Rule 13.1.

THIS PAGE BLANK (USPTO)